FAP and Miyoshi myopathy: MM-BMSCs act as a protectant for bortezomib-induced apoptosis in MM cells through FAPα/β-catenin pathway [12]; however, the other tumor promoting effect, such as immunosuppression, has not yet been fully elucidated.